Form 4: Nuvalent Director Matthew Shair Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Matthew Shair, a director at Nuvalent, Inc., executed multiple sales of Class A Common Stock on April 29, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On April 29, 2024, Matthew Shair, a director of Nuvalent, Inc., sold shares of Class A Common Stock.
- The sales were executed under a Rule 10b5-1 trading plan adopted on December 21, 2023.
- A total of 37,500 shares were sold directly at weighted average prices ranging from $67.01 to $68.57.
- Additionally, 1,999 shares held indirectly through the Matthew D. Shair 2021 Irrevocable Family Trust were sold at weighted average prices ranging from $67.01 to $68.57.
- Following these transactions, Shair directly owns 1,499,698 shares and indirectly owns 236,522 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transactions were pre-planned under a Rule 10b5-1 trading plan and do not necessarily reflect a change in the director's view of the company's prospects.
Industry Context
Sales by company insiders are a common occurrence and are often pre-planned through Rule 10b5-1 trading plans to avoid accusations of insider trading. The market typically analyzes these sales in the context of the company's overall performance and future prospects.
Comparison to Industry Standards
- It's common for directors and officers of publicly traded companies, such as Nuvalent, to utilize 10b5-1 trading plans to sell shares over time.
- These plans are often adopted to diversify personal holdings or for estate planning purposes.
- The volume and frequency of these sales are generally compared to industry peers like Relay Therapeutics or Black Diamond Therapeutics to gauge investor sentiment.
Stakeholder Impact
- The sale of shares by a director could be perceived negatively by some shareholders, potentially leading to slight downward pressure on the stock price in the short term.
- However, the existence of a 10b5-1 trading plan mitigates this concern as it indicates the sales were pre-planned.
Key Dates
| Date | Description |
|---|---|
| 12/21/2023 | Date the Rule 10b5-1 trading plan was adopted by the reporting person. |
| 04/29/2024 | Date of the transactions (sale of Class A Common Stock). |
| 05/01/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.